Smartleaf Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-206
Closed -$10.9K – 3505
2026
Q1
$10.9K Buy
206
+174
+544% +$7.15K ﹤0.01% 2284
2025
Q4
$1.3K Buy
+32
New +$740 ﹤0.01% 3111

Other funds holding TERN

Smartleaf Asset Management's TERN Position: Q2 2026 in Review

Smartleaf Asset Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 206 shares — an estimated $10.9K sold.

Smartleaf Asset Management first reported a position in TERN in Q4 2025 and held it in 2 quarters. The position peaked at $10.9K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Smartleaf Asset Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Smartleaf Asset Management sold 206 Terns Pharmaceuticals shares in Q2 2026, an estimated $10.9K.
  • Smartleaf Asset Management first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Smartleaf Asset Management's Terns Pharmaceuticals position peaked at $10.9K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.